Protalix Biotherapeutics
Protalix Biotherapeutics – a biopharmaceutical company using a plant cell-based platform named ProCellEx – has appointed Teva’s former CEO to its Board of Directors. Shlomo Yanai, who headed Teva from 2007 to 2012, succeeded Zeev Bronfeld as Chairman of Protalix last Thursday.
Bronfeld will remain a member of the Board. He commented that Yanai “brings extensive knowledge and vast experience from his years as CEO at Teva Pharmaceutical Industries and Makhteshim Agan.” Yanai said he was joining the company in time to work on “the promising pipeline coming from ProCellEx technology as well as building the market for Elelyso.”
Before heading up Teva, Yanai was President and CEO of Makhteshim Agan Industries (now Adama), an agro-chemicals company. He has also served as a member of the Board of Directors of the Bank Leumi Le-Israel, LycoRed Natural Products Industries and ITL Optronics Ltd. He served in the Israeli Army as head of the Strategy Planning Branch of General Headquarters of the Israel Defence Forces and retired in 2001 at the rank of Major General.